Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.